EFUDIX

This brand name is authorized in Australia, Estonia, France, Ireland, Israel, Malta, Mexico, Netherlands, New Zealand, Poland, Turkey, United Kingdom, South Africa

Active ingredients

The drug EFUDIX contains one active pharmaceutical ingredient (API):

1 Fluorouracil
UNII U3P01618RT - FLUOROURACIL

Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine – which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the “S” phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand. Fluorouracil is used for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Read about Fluorouracil

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
EFUDIX Cream Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01BC02 Fluorouracil L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 4222F
Country: EE Ravimiamet Identifier(s): 1162842
Country: FR Base de données publique des médicaments Identifier(s): 60627235
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 111309, 196930, 375759, 375760
Country: IE Health Products Regulatory Authority Identifier(s): 64351, 64360
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7198
Country: MT Medicines Authority Identifier(s): MA1507/00801, PI565/23403A
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 77246
Country: NL Z-Index G-Standaard, PRK Identifier(s): 2585
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 1901
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100021476
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8698856350350, 8698856350367
Country: ZA Health Products Regulatory Authority Identifier(s): D/13.8/122

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.